Qualigen therapeutics announces first patient dosed in the phase 1a clinical trial of qn-302 for treatment of advanced or metastatic solid tumors

Carlsbad, calif., nov. 07, 2023 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, announces today that the first patient in the phase 1a clinical trial has been dosed with qn-302, a potential first-in-class, investigational g-quadruplex (g4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors. the first clinical site is located at start midwest in grand rapids, michigan.
QLGN Ratings Summary
QLGN Quant Ranking